Drugs / PATH-wSP
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02543892 | Aug 2016 → Jan 2018 | pneumonia | PATH | Completed | No outcome recorded |
| Phase 1/2 | NCT02097472 | Apr 2014 → Dec 2015 | streptococcal pneumonia | PATH | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PATH wSP | “A single-vial formulation of PATH wSP, an adsorbed suspension of SPWCV and Alum, has now been manufactured by PT Bio Farma, Indonesia.” NCT02543892 ↗ |
| Known as | SPWCV | “S. pneumoniae whole cell vaccine (SPWCV) is a vaccine candidate made from whole, unencapsulated pneumococcal cells.” NCT02097472 ↗ |
| Modality | Vaccine | “S. pneumoniae whole cell vaccine (SPWCV)” NCT02097472 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT02097472 ↗ |